0000899243-22-039460.txt : 20221228
0000899243-22-039460.hdr.sgml : 20221228
20221228183033
ACCESSION NUMBER: 0000899243-22-039460
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20221227
FILED AS OF DATE: 20221228
DATE AS OF CHANGE: 20221228
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Young Jonathan
CENTRAL INDEX KEY: 0001779805
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38944
FILM NUMBER: 221495999
MAIL ADDRESS:
STREET 1: C/O AKERO THERAPEUTICS, INC.
STREET 2: 170 HARBOR WAY 3RD FL
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Akero Therapeutics, Inc.
CENTRAL INDEX KEY: 0001744659
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 601 GATEWAY BOULEVARD, SUITE 350
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650-487-6488
MAIL ADDRESS:
STREET 1: 601 GATEWAY BOULEVARD, SUITE 350
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-12-27
0
0001744659
Akero Therapeutics, Inc.
AKRO
0001779805
Young Jonathan
C/O AKERO THERAPEUTICS, INC.
601 GATEWAY BOULEVARD, SUITE 350
SOUTH SAN FRANCISCO
CA
94080
0
1
0
0
Chief Operating Officer
Common Stock
2022-12-27
4
M
0
722
0.615
A
183171
D
Common Stock
2022-12-27
4
M
0
11778
6.36
A
194949
D
Common Stock
2022-12-27
4
S
0
12500
49.5687
D
182449
D
Common Stock
20000
I
By EA Irrevocable Trust
Common Stock
20000
I
By CM Irrevocable Trust
Common Stock
20000
I
By JL Irrevocable Trust
Employee Stock Option (Right to Buy)
6.36
2022-12-27
4
M
0
11778
0.00
D
2029-01-15
Common Stock
11778
48478
D
Employee Stock Option (Right to Buy)
0.615
2022-12-27
4
M
0
722
0.00
D
2028-10-17
Common Stock
722
92098
D
The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated June 9, 2021, previously adopted by the reporting person.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $49.50 to $49.75, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4.
These shares are held in irrevocable trusts for the benefit of the reporting person's children. The reporting person's spouse is trustee of the trusts. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
This option shall vest and become exercisable in 48 equal monthly installments, commencing on January 1, 2019.
The options are vested and currently exercisable.
/s/ Jonathan Young
2022-12-28